RT Generic
T1 SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
A1 Guma, Josep
A1 Palazon-Carrion, Natalia
A1 Rueda-Dominguez, Antonio
A1 Sequero, Silvia
A1 Calvo, Virginia
A1 Garcia-Arroyo, Ramon
A1 Gomez-Codina, Jose
A1 Llanos, Marta
A1 Martinez-Banaclocha, Natividad
A1 Provencio, Mariano
K1 Diagnosis
K1 Diffuse large B-cell lymphoma
K1 Guideline
K1 Treatment
AB Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.
PB Springer
SN 1699-3055
YR 2023
FD 2023-06-08
LK https://hdl.handle.net/10668/28551
UL https://hdl.handle.net/10668/28551
LA en
NO Gumà J, Palazón-Carrión N, Rueda-Domínguez A, Sequero S, Calvo V, García-Arroyo R, et al. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clin Transl Oncol. 2023 Sep;25(9):2749-2758
DS RISalud
RD Sep 19, 2025